Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body's natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley's Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company's existing investors.

Leo Cancer Care's first product, Marie, named after physicist Marie Curie, is an upright patient positioning system and CT scanner for proton therapy that replaces gantry rotation with patient rotation. Marie reduces the size, cost, and complexity of proton therapy, making these treatments more patient-friendly and globally accessible.